To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs
- Registration Number
- NCT05699408
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Brief Summary
The study is being conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type 2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 513
Inclusion Criteria
- Diagnosed with type 2 diabetes ≥ 6 months；
- Stable daily dose(s) for ≥8 weeks prior to screening of any of the following anti-diabetic drug(s) or combination regimen(s): 1) Any metformin formulations ≥1500 mg daily or maximum tolerated (≥1000mg daily). 2) Any of the following oral antidiabetic drugs with dose ≥half of the maximum approved dose according to local label or maximum tolerated): Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, Sodium-glucose co-transporter-2 (SGLT2) inhibitors, Thiazolidinediones and Alpha-glucosidase inhibitors.
- Glycated hemoglobin was 7.0%~11.0% (both inclusive) at screening
Exclusion Criteria
- Known or suspected allergy or intolerance to the investigational medicinal products or related products；
- Hospitalization for diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome during the previous 6 months；
- Potentially unstable diabetic retinopathy or maculopathy requiring treatment (e.g., laser, surgical treatment or injectable drugs) during the previous 6 months；
- Have used insulin therapy anytime in the past 2 years, except for short-term insulin treatment and prior treatment for gestational diabetes.
- Participation in any clinical trial of an approved or non-approved investigational product/treatment within the last 1 month or 5 half-lives, whichever is longer, prior to screening;
- Women who are pregnant, breastfeeding or planning to conceive, or women of childbearing potential are reluctant to use appropriate contraception during the trial and for at least 14 days after the last dose of the investigational medicinal drug;
- Any conditions that the Investigator judges might not besuitable to participate in the trial.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description INS068 injection INS068 injection - Insulin Glargine Insulin Glargine -
- Primary Outcome Measures
Name Time Method Change in HbA1c Week 0 to Week 26 Change from baseline in Glycosylated Haemoglobin after 26 weeks of treatment
- Secondary Outcome Measures
Name Time Method Change in scores of diabetes treatment satisfaction questionnaire status version (DTSQs) Week 0 to Week 26 、Week 0 to Week 52 Change in HbA1c Week 0 to Week 52 Anti-drug Antibodies Week 0 to Week 52 + 14 days follow-up Frequency and severity of adverse events Week 0 to Week 52 + 14 days follow-up Incidence and rate of Hypoglycemic events Week 0 to Week 52 + 14 days follow-up Average daily Insulin dose Week 0 to Week 26 、Week 0 to Week 52 Proportion of Subjects requiring rescue therapy during treatment Week 0 to Week 26 、Week 0 to Week 52 Change in FPG(fasting plasma glucose) Week 0 to Week 26, Week 0 to Week 52 Change from baseline in FPG after 26 weeks and 52 weeks of treatment
Proportion of Subjects with HbA1c<7% and HbA1c≤6.5% Week 0 to Week 26 、Week 0 to Week 52 Proportion of subjects with HbA1c\<7% and HbA1c≤6.5% after 26 weeks and 52 weeks of treatment
per-breakfast SMPG Week 0 to Week 26 、Week 0 to Week 52 8-point SMPG profiles Week 0 to Week 26 、Week 0 to Week 52 Proportion of Subjects achieving HbA1c targets (HbA1c<7%; HbA1c≤6.5%) and without grade 2 or 3 hypoglycaemia in the last 12 weeks of the treatment period Week 0 to Week 26, Week 0 to Week 52 Change in weight Week 0 to Week 26、Week 0 to Week 52 Serum INS068 concentration Week 0 to Week 52
Trial Locations
- Locations (1)
Peking University People's Hospital
🇨🇳Beijing, Beijing, China